Monday, February 10

Health

Evaluation of the benefits of dialysis in prolonging the life of elderly patients
Health

Evaluation of the benefits of dialysis in prolonging the life of elderly patients

Related media - Breaking news Health researchers often scrutinize various medical treatments to determine their effectiveness, especially for older adults. One noteworthy study, published in the Annals of Internal Medicine, examined the impact of dialysis on older patients with kidney failure, revealing mixed results. The study focused on more than 20,000 veterans, with an average age of 78, and used a simulated trial to explore survival outcomes. The results indicated that starting dialysis immediately after diagnosis only marginally extended life expectancy by about 77 days over three years compared to those who never received dialysis. Georgia Outlaw, a 77-year-old retiree from Williamston, North Carolina, chose to forgo dialysis despite her advanced kidney disease. Her e...
Study finds anti-obesity drugs may reduce mortality in Covid-19
Health

Study finds anti-obesity drugs may reduce mortality in Covid-19

Related media - Recent news Recent research has highlighted a potentially game-changing secondary benefit of Wegovy, an established obesity management drug. In a large clinical trial, individuals taking Wegovy were observed to have a significantly reduced death rate from Covid-19 compared to those not taking the drug. Clinical Trial Insights The study participants, who were already using Wegovy for obesity, contracted Covid-19 at the usual rate expected in the general population. However, their risk of succumbing to the virus was reduced by a third. This remarkable reduction in mortality was surprising and suggests an indirect benefit of the drug that had not previously been recognized. Wider health implications In addition to COVID-19 mortality, the study also documen...
Growing Concern Over Eastern Equine Encephalitis in Northeastern United States
Health

Growing Concern Over Eastern Equine Encephalitis in Northeastern United States

Related media - Recent news Health officials in the Northeast United States are stepping up warnings about Eastern Equine Encephalitis (EEE), a rare but potentially fatal mosquito-borne virus. Recent outbreaks have prompted increased vigilance and preventative measures in several states. Increased risk and community responses The resurgence of EEE has led to increased precautions, particularly in Massachusetts, where residents in several communities are advised to limit outdoor activities from dusk until dawn to avoid exposure to mosquitoes. This advice is underscored by the recent overnight closures of several parks and the tragic death of a person in New Hampshire from the virus. Understanding Eastern Equine Encephalitis Eastern equine encephalitis is a serious viral...
Living with Covid: A New Era of Risk Management
Health

Living with Covid: A New Era of Risk Management

Related media - Latest news The summer of 2024 sees a surge in Covid cases, yet many Americans treat it like the common cold. Gone are the days of widespread testing, isolation, and mask-wearing. This newfound nonchalance is partly due to pandemic fatigue, but it also reflects a growing sense that Covid is here to stay. Epidemiologists acknowledge this shift, noting that Covid is likely moving from a pandemic to an endemic disease. While some vulnerable populations remain at high risk, the overall threat appears to be muted due to increased immunity from vaccination and earlier infections. That doesn’t mean Covid is harmless. The recent surge demonstrates its continued presence, and unknowns such as long-term effects and the evolution of variants remain. Public health offici...
Failures in Psychedelic Medicine: A Reality Check for Research Integrity
Health

Failures in Psychedelic Medicine: A Reality Check for Research Integrity

Related media - Latest news It’s been a year of anticipation for Lykos Therapeutics, as they await a landmark decision from the Food and Drug Administration (FDA). The drugmaker had filed an application to approve MDMA as a treatment for PTSD, expecting a positive outcome that would catapult them to new heights. However, on August 9, the FDA responded with a rebuttal, culminating growing concerns about the quality of Lykos’ clinical trials. Following the decision, the journal Psychopharmacology retracted three studies related to MDMA research, citing unethical practices and making serious allegations, including sexual misconduct by an unlicensed therapist at one of the study sites. Many of the authors implicated in these retractions had ties to Lykos. This development ...